Imiquimod cream is a topical immune response modifier primarily used for the treatment of external genital/perianal warts and actinic keratosis.

I. Indications

1. Condylomata Acuminata (External Genital or Perianal Warts)

(1) This product is indicated only for the treatment of condylomata acuminata on the external genitalia or perianal skin.

(2) Diagnosis must be confirmed by a physician before use. It is not indicated for warts in other locations.

2. Actinic Keratosis (on the Face or Balding Scalp)

(1) Indicated for actinic keratosis on the face or balding scalp.

(2) Safety and efficacy have not been established for actinic keratosis on other body sites.

(3) Prior to treatment, clinically atypical lesions (e.g., those suspicious for invasive squamous cell carcinoma) should be evaluated, and biopsy should be performed if necessary to rule out invasive disease.

3. Mechanism of Action

Imiquimod works primarily by inducing cytokines such as interferon-α, activating local cellular immune responses, thereby inhibiting viral proliferation and clearing abnormal proliferating cells.

II. Contraindications

1. Absolute Contraindications

(1) Patients with a history of hypersensitivity to any component of this product should not use it.

(2) Prior history of allergic reactions, including to excipients (e.g., methylparaben, propylparaben), should be confirmed before use.

2. Prohibited Application Sites

(1) This product should not be used on mucosal surfaces including intraurethral, intravaginal, cervical, intrarectal, or internal anal areas.

(2) Mucous membranes in these areas are highly sensitive to the drug, and severe local reactions such as pain, edema, dysuria, or defecation difficulty may occur.

3. Avoid Contact with Eyes, Mouth, and Nose

The product labeling explicitly states that the cream should not come into contact with the eyes, lips, or nostrils to avoid irritation and injury.

4. Do Not Use on Broken Skin

Do not apply to open wounds or broken skin, as this may exacerbate local inflammation and delay healing.

5. Discontinue Use if Inflammation Has Not Resolved

If local skin still shows signs of inflammation due to other medications or surgical procedures, use of this product should be delayed until full recovery, otherwise inflammation may worsen.

III. Use in Special Populations

1. Pregnant Women

(1) Use only if the potential benefit to the mother justifies the potential risk to the fetus.

(2) Adequate human pregnancy studies are lacking.

2. Breastfeeding Women

Avoid applying cream to the breast or areola areas, and wash hands and chest thoroughly before nursing.

3. Children

Safety and effectiveness in pediatric patients have not been established.

4. Elderly

No specific precautions for the elderly are listed in the labeling; generally, adult dosing may be followed, but care should be taken as the skin may be thinner and healing capacity reduced, avoiding excessive application.

5. Immunocompromised Patients

(1) In immunocompromised states (e.g., post-transplant, undergoing chemotherapy, or HIV infection), imiquimod may not achieve the expected efficacy.

(2) The product labeling states that efficacy has not been established in immunocompromised patients; use with caution.

6. Patients with Chronic GVHD or Autoimmune Diseases

In conditions such as systemic lupus erythematosus or scleroderma, use of this product may exacerbate skin inflammation or trigger disease activity; discontinuation should be considered if worsening occurs.

7. Male Patients with Phimosis or Paraphimosis Tendency

During treatment, the foreskin should be retracted daily and kept clean and dry to reduce the risk of redness, erosion, and edema.